Key result
This review discusses the pros and cons of various in vivo and in vitro animal models for assessing the proarrhythmia liability of drugs.
This review highlights the importance and characteristics of in vitro and in vivo animal models for early identification of drug-induced proarrhythmia liability.
Animal models may enable early QT-prolonging drug screening; leaves open their predictive value for human TdP risk.
The steadily increasing list of drugs associated with prolongation of the QT interval and torsades de pointes (TdP) constitute a medical problem of major concern. Hence, there is a need at an early stage to identify drug candidates with an inherent capacity to induce repolarization-related proarrhythmias, avoiding exposure of large populations to potentially harmful drugs. Furthermore, the availability of clinically relevant and predictive animal models should reduce the risk that effective and potentially life-saving drugs never reach the market. This review will discuss the pros and cons of some in vivo and in vitro animal models for assessing proarrhythmia liability.
No takes yet. Share an insight, caveat, or question.
Leif Carlsson (2005) conducted a review in Drug-induced QT prolongation and torsades de pointes. In vitro and in vivo animal models was evaluated. This review discusses the pros and cons of various in vivo and in vitro animal models for assessing the proarrhythmia liability of drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: